- Home
- CAPR vs RCKT Comparison
CAPR vs RCKT Comparison
Compare CAPR & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- RCKT
- Stock Information
- Founded
- CAPR 2005
- RCKT 1999
- Country
- CAPR United States
- RCKT United States
- Employees
- CAPR N/A
- RCKT N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- CAPR Health Care
- RCKT Health Care
- Exchange
- CAPR Nasdaq
- RCKT Nasdaq
- Market Cap
- CAPR 322.7M
- RCKT 328.6M
- IPO Year
- CAPR N/A
- RCKT N/A
- Fundamental
- Price
- CAPR $7.10
- RCKT $3.64
- Analyst Decision
- CAPR Strong Buy
- RCKT Buy
- Analyst Count
- CAPR 8
- RCKT 13
- Target Price
- CAPR $24.75
- RCKT $12.96
- AVG Volume (30 Days)
- CAPR 1.7M
- RCKT 5.8M
- Earning Date
- CAPR 08-11-2025
- RCKT 08-07-2025
- Dividend Yield
- CAPR N/A
- RCKT N/A
- EPS Growth
- CAPR N/A
- RCKT N/A
- EPS
- CAPR N/A
- RCKT N/A
- Revenue
- CAPR $13,392,150.00
- RCKT N/A
- Revenue This Year
- CAPR $16.24
- RCKT N/A
- Revenue Next Year
- CAPR $328.11
- RCKT $591.46
- P/E Ratio
- CAPR N/A
- RCKT N/A
- Revenue Growth
- CAPR N/A
- RCKT N/A
- 52 Week Low
- CAPR $3.98
- RCKT $2.19
- 52 Week High
- CAPR $23.40
- RCKT $22.01
- Technical
- Relative Strength Index (RSI)
- CAPR 42.24
- RCKT 62.31
- Support Level
- CAPR $6.90
- RCKT $2.88
- Resistance Level
- CAPR $8.00
- RCKT $4.10
- Average True Range (ATR)
- CAPR 0.55
- RCKT 0.26
- MACD
- CAPR -0.02
- RCKT 0.09
- Stochastic Oscillator
- CAPR 7.91
- RCKT 63.78
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.